Category Archives: AFTNews

PRNews

Fiasp(R) Significantly Improved Overall Blood Sugar Control in Type 1 Diabetes Long-term

LISBON, Portugal, Sept. 12, 2017 /PRNewswire/ — Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]–[3] mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings[4].

The findings were presented today at the 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, and showed that Fiasp® maintained the significant improvement in overall blood sugar control that was seen in a shorter-term (26 weeks) study period[1]. The results also reconfirmed the safety profile of Fiasp®, showing comparable overall numbers of severe or blood-sugar confirmed hypoglycaemia (low blood sugar levels)[4].

“These results provide reassurance of the meaningful long-term benefits of Fiasp® versus conventional insulin aspart,” said Professor Chantal Mathieu, study investigator, chair of Endocrinology and professor of Medicine at Katholieke Universiteit Leuven, Belgium. “Accordingly, for people with diabetes who struggle to control their post-meal sugar levels, Fiasp® might offer a better option to meet their needs.”

After eating, blood sugar levels rise rapidly. In diabetes, the body either cannot bring these high sugar levels down, or struggles to do so. Sustained high post-meal sugar levels are associated with an increased risk of cardiovascular disease and other diabetes-related complications, including damage to eyes and kidneys and cancer[5],[6]. High post-meal sugar levels also contribute to inadequate overall blood sugar control[2],[5],[7].

While mealtime insulins aim to bring post-meal sugar levels down, conventional rapid-acting insulins are not as fast as the speed of the natural physiological insulin response. Due to this slower response, people with diabetes can remain in an elevated post-meal sugar state for an extended period[2].

“Compared to conventional insulin aspart, Fiasp® is a closer match to the natural physiological insulin response, leading to better long-term blood sugar control,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “Fiasp® delivers benefits for people with diabetes, helping them to achieve better post-meal and overall blood sugar control.”

About the study 

The onset 1 trial (1,143 people randomised) was a phase 3a, partially double-blind, basal-bolus, treat-to-target trial, evaluating the efficacy and safety of Fiasp® compared with conventional insulin aspart in type 1 diabetes over 52 weeks, in two 26 week treatment periods. The findings from the 52 week study period were presented at the EASD Annual Meeting 2017.

In the 52 week study period, Fiasp® demonstrated a statistically significantly greater overall blood sugar reduction of -0.10% in adults with type 1 diabetes, in comparison to conventional insulin aspart. Fiasp® also showed a statistically significant reduction in 1-hour post-meal sugar increment of -0.91 mmol/L; no significant difference was seen in 2-hour post-meal sugar increment, compared with conventional insulin aspart. These results were achieved with a comparable overall rate of severe or blood-sugar confirmed hypoglycaemia between the two treatments[4].

About Fiasp® 

Fiasp® is the only approved, new-generation, ultra-fast acting[1]–[3] mealtime insulin. Fiasp® is insulin aspart in an innovative formulation, in which two excipients have been added: Vitamin B3 (niacinamide) to increase the speed of absorption and a naturally occurring amino acid (L-Arginine) for stability[8].

Fiasp® received marketing authorisation from the European Commission on 9 January, from Health Canada on 6 January, from Swissmedic on 7 June and from the Australian Government Department of Health on 28 June 2017. It is currently under regulatory review in over 10 countries.

After receiving a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in October 2016, Novo Nordisk resubmitted the fast-acting insulin aspart new drug application (NDA) as a class II resubmission on 29 March 2017 and FDA approval is expected at the end of Q3 2017.

About Novo Nordisk 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube 

References 

  1. Russell-Jones D, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017; 40(7):943-50.
  2. Heinemann L and Muchmore DB. Ultrafast-acting insulins: state of the art. Journal of Diabetes Science and Technology 2012; 6(4):728-42.
  3. Cengiz E, et al. Moving toward the ideal insulin for insulin pumps. Expert Review of Medical Devices 2016; 13(1):57-69.
  4. Mathieu C, et al. Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: comparison with insulin aspart in onset 1. Poster presentation at the 53rd EASD Annual Meeting. 11-15 September 2017; Lisbon, Portugal.
  5. Madsbad S. Impact of postprandial glucose control on diabetes-related complications: how is the evidence evolving? Journal of Diabetes and Its Complications 2016; 30(2):374-85.
  6. International Diabetes Federation (IDF). Guideline for management of postmeal glucose in diabetes. 2011.
  7. Monnier L, et al. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technology & Therapeutics 2011; 13(Suppl.1):25-32.
  8. Heise T, et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clinical Pharmacokinetics 2017; 56(5):551-9.

Further information
Media:        
Katrine Sperling
+45-3079-6718    
krsp@novonordisk.com

Åsa Josefsson
+45-3079-7708
aajf@novonordisk.com

Investors:        
Peter Hugreffe Ankersen  
+45-3075-9085
phak@novonordisk.com

Hanna Ögren
+45-3079-8519
haoe@novonordisk.com

Anders Mikkelsen
+45-3079-4461  
arm@novonordisk.com

Christina Jensen
+45-3079-3009  
cnje@novonordisk.com

Kasper Veje (US)
+1-609-235-8567  
kpvj@novonordisk.com 

ZINC#: HQMMA/FA/0717/0218

Date of preparation: August 2017

PRNews

Unleashing the Power of the Latest Pharmaceutical Research for Simplified Global Healthcare Solutions through Conference Series Pharma meetings

Conference Series has scheduled 300 more Pharma meetings for 2018 in 30+ countries

LONDON, and SINGAPORE, Sept. 12, 2017 /PRNewswire/ — Associated with over 1000 scientific societies and organizations, Conference Series is scheduled to organize pharmaceutical conferences in Europe, USA, and Asia Pacific with a view to unleash precious scientific findings for the benefit of humanity.

With the changing face of pharmaceutical markets around the world, the industry exhibits enormous potential exponential growth. In the US, healthcare spending is in the range of $3.12 trillion with pharmaceutical sales of around $333 billion. Of this, $244 billion comes from patented sales and $70 billion from generic sales. Considering this vast economy in the pharmaceutical field, we at Conference Series are organizing some of our best conferences in the USA, Europe and Asia-Pacific regions on the current topics, which are instrumental in the changing landscape of the pharmaceutical market.

Our pharmaceutical conferences scheduled during 2018 span all over the world and feature several pharmaceutical topics like drug delivery systems, drug discovery, drug designing, pharmacology, neuropharmacology, bioavailability bioequivalence studies, biopharmaceutical drug discovery, antibiotics, toxicology, clinical trials, best compliance methods, regulatory frameworks and other related topics. Conference Series Pharmaceutical meetings promote extended networking between experts and address all such challenges, which require early troubleshooting. Attendees of the conferences witness several hours of pharmaceutical knowledge exchange and sharing that would inevitably boost scientific research and developments in the pharmaceutical sciences.

ConferenceSeries and its partnered companies organise 3000+ conferences across the USA, Europe & Asia and publish 1000+ Peer Reviewed Journals, which attract over 50 million readers and feature over 50,000 eminent personalities and reputed scientists as editorial board members.

During these conferences we have also partnered with some of the best pharmaceutical and healthcare companies around the globe who are not only pioneers in drug discovery, but also the market leaders in terms of revenue, to unveil their latest discoveries. Reputed universities across the USA, UK, Europe and Asia grace these conferences with a view to promote industry-academia collaborations. These pharma conferences witness a web traffic total of one million visits, whereas the total page views are 4 million (analyzed twice a year).

For a glimpse of our conferences and testimonials visit our Conference Gallery & Meetings Experts Outlook

For assistances on registrations/exhibitions and other details Contact:

T: +1-650-889-4686
E: contact@conferenceseries.com

Logo – https://mma.prnewswire.com/media/554693/Conference_Series_Logo.jpg

PRNews

Merck Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance

DARMSTADT, Germany, Sept. 11, 2017 /PRNewswire/ —

Not intended for U.K./U.S. based media 

  • Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care  
  • Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes 
  • Focused on areas of high unmet need to help enhance advancement in understanding, and empower and connect oncology community  

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium, to jointly lead the Global Oncology Big Data Alliance (GOBDA). This was announced at the signing of a Memorandum of Understanding yesterday, to coincide with Merck’s Award Ceremony announcing the recipients of its 2017 Grant for Oncology Innovation, held during the annual European Society for Medical Oncology Congress (ESMO 2017) in Madrid, Spain.

“The ultimate goal of our alliance with Project Data Sphere is to unleash the power of big data to bring value to cancer patients,” said Belen Garijo, Member of the Executive Board of Merck and CEO Healthcare. “Merck is deeply committed to investing in initiatives that push the boundaries of cancer research, that we hope will accelerate the discovery, development and delivery of innovative treatments to all who need it.”

The GOBDA initiative has been formed to expand the open-access of de-identified patient data sets to further enhance analytical capabilities, by building on Project Data Sphere’s innovative digital platform. The current platform contains historical clinical trial data from almost 100,000 patients provided by multiple organizations, and access to this information has already led to new and potentially practice-changing findings. GOBDA will expand this platform to include rare tumor trial, experimental arm and real-world patient data. Leveraging these data with big data analytics will help to optimize clinical trials, build a registry of data and help to enable advancement in the understanding of cancer treatment globally, with the mission to address the significant unmet needs in this field. In addition, by unleashing analytical power and big data to study and learn how to better manage rare but serious immune-mediated adverse events, institutes and industry will be able to assist regulators to adapt these new learnings into treatment guidelines. As well as establishing models to help enable early adverse event identification and improved patient outcomes.

“Big data is changing the face of healthcare as we know it, and advances in our ability to collect data, share and analyze it has already led to ground-breaking work,” said Dr Martin J. Murphy, CEO of Project Data Sphere LLC. “The joint force of Merck and Project Data Sphere will aim to connect and empower a truly global oncology community with these big data and analytical capabilities. We are excited about the Global Oncology Big Data Alliance initiative and the continuing engagement of a diverse community focused on finding solutions for cancer patients.”

Investment in the initiative builds on Merck’s commitment to rewarding innovation and creative thinking that could further advance the field of medicine, and begins a new chapter for global oncology innovation. Since 2014, the company has awarded a total of €4 million to further research in oncology through the Grant for Oncology Innovation award, which has engaged over 1,000 investigators worldwide, generated 12 winning research proposals from leading academic institutions, and generated seven high impact manuscripts. More information about the program can be found online at: http://www.grantforoncologyinnovation.org

About Project Data Sphere, LLC 

Project Data Sphere, LLC is an independent, not-for-profit initiative of the CEO Roundtable on Cancer Inc.’s Life Sciences Consortium. The CEO Roundtable on Cancer is a 501(c)(3) nonprofit corporation founded by President George H.W. Bush in 2001 to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to the best available treatments, and hasten the discovery of novel and more effective anti-cancer therapies.

For more information, visit http://www.ProjectDataSphere.org, or follow the Project Data Sphere initiative on Twitter at https://twitter.com/ProjDataSphere.

About the Global Oncology Big Data Alliance (GOBDA) 

The Global Oncology Big Data Alliance (GOBDA) will be a joint alliance, co-led by Merck and Project Data Sphere with the shared vision to connect and empower the oncology community with big data and advanced analytical capabilities. It is the goal of the initiative that by unleashing these data capabilities, this platform will help accelerate discovery, development and delivery of innovative treatment approaches for cancer patients, and address current significant unmet needs in this field.

A joint steering committee will monitor the initial progress of the collaboration including expansion of the PDS database with new data sets provided by the National Cancer Institute and other parties, designing the first FDA/Industry immuno-related adverse event Safety Meeting on December 15, 2017. The anticipated overall term of the GOBDA project and strategic collaboration shall be from 2018-2021.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR 15.0 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Your Contact: Martina Brunner +49-6151-72-43959

PRNews

Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated in MOSAIC Study

LAUSANNE, Switzerland, Sept. 11, 2017 /PRNewswire/ — Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology.

“This is the first study evaluating the benefit of using both ivermectin 1% and brimonidine 0.33% in combination to effectively target the multiple features of rosacea,“ commented study author Linda Stein Gold, Henry Ford Hospital, Detroit, MI. “This study develops a comprehensive and early treatment approach to this complex disease.“

“The visible signs of rosacea can significantly impact patients‘ quality of life,“ said Gregor Schaefer, Medical Lead at Galderma. “Galderma is committed to supporting patients through the development of practical treatment options.“

Reference:  

Stein Gold L, et al. J Drugs Dermatol. 2017;16(9):909-916.

About Rosacea 

Rosacea is a common inflammatory skin disease that presents variable clinical characteristics, of which the most common are flushing, permanent erythema, and inflammatory lesions. It mainly affects the central areas of the face, such as the cheeks and nose. The disease can affect both adult men and women, usually after the age of 30. Additionally, symptoms such as stinging, burning and increased sensitivity of the skin are common. The eyes are often affected, and might present as red, dry or itchy.

Although the cause of the disease is still under debate, various trigger factors are known, including spicy foods, alcohol, emotional stress, sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites, can also be found in the skin in an elevated quantity in people with rosacea.

Rosacea may worsen over time if left untreated. People that suspect they suffer from rosacea should visit their dermatologist or healthcare provider for diagnosis and discuss what treatment is right for them. Because rosacea is a highly visible disease, it is known to cause embarrassment and anxiety in some patients, which in turn may cause frustration and have a negative impact on their social life.

About Galderma 

Galderma, Nestle Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically defined and medically proven solutions for the skin, hair and nails. For more information, please visit http://www.galderma.com

PRNews

Frost & Sullivan Applauds STANLEY Healthcare’s Design Innovation and Leadership in Addressing the Changing Needs of the Senior Living Industry

STANLEY Healthcare’s user-friendly, unobtrusive innovations address challenges in the market, making senior living communities tech savvy and future ready for implementing efficient senior care

SANTA CLARA, California, Sept. 7, 2017 /PRNewswire/ — Based on its recent analysis of the market for technology solutions for senior living communities, Frost & Sullivan recognizes STANLEY Healthcare with the 2017 Global Company of the Year Award. STANLEY Healthcare, a business unit of the Fortune 500 Company Stanley Black & Decker, is a leading solutions vendor for hospitals, health systems, and the senior living space. STANLEY Healthcare aims to expand its suite of solutions for the senior living market and deliver greater value to its clients in supporting their provision of senior care in an increasingly challenging environment.


STANLEY Healthcare receives the 2017 Global Senior Living Community Vendor Company of the Year Award

STANLEY Healthcare’s solutions serve several safety and security needs of senior living communities. These solutions include emergency call, wander management, staff security, facility security, and temperature monitoring. STANLEY Healthcare is the leader in fall management solutions, with over a million fall monitors installed over the past decade.

Going beyond its existing solutions and realizing the industry’s upcoming needs, STANLEY Healthcare is working to realize the ‘Smart Resident Room’. Integrating sensors in an Internet of Things fashion, the Smart Room concept will enable senior living communities to monitor residents unobtrusively while they carry on with their daily activities.

“Realizing the nature of technology and acknowledging the fast-changing pace of advancements, STANLEY Healthcare routinely partners with other technology companies whose solutions can integrate with its own to provide enhanced value for its customers,” said Industry Analyst Siddharth Shah at Frost & Sullivan. “It also partners with some of the WLAN and infrastructure providers to ensure its products and software work seamlessly with customers’ wireless infrastructure.”

An example of innovative technology founded on market needs is a wander management system using Bluetooth Low Energy (BLE) for wireless communication. “To lower the barriers to entry for wireless solutions, STANLEY Healthcare is moving towards using BLE solutions. Designing solutions that are appealing enough to attract residents is an approach that helps STANLEY Healthcare differentiate its solutions from others available in the senior living space,” said Shah.

Another key differentiator that distinguishes STANLEY Healthcare from the competition is its approach to customer care, including:

  • Product support services spanning the entire lifecycle of the solution.
  • The By Your Side™ customer support portal, which helps clients obtain answers to their queries, provides access to product documentation, and extends support for solving technical challenges.
  • 24/7 phone support, remote diagnostics, and on-site repair services.

Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to execute successfully a competitive strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About STANLEY Healthcare

STANLEY Healthcare provides over 5,000 acute care hospitals and 12,000 long-term care organizations with enterprise solutions that create a safe, secure and efficient healthcare experience across life’s stages. The STANLEY Healthcare solution set enables customers to achieve organizational excellence and superior care in critical areas: Patient/Resident Safety, Security & Protection, Environmental Monitoring, Clinical Operations & Workflow and Supply Chain & Asset Management. These solutions are complemented by STANLEY Healthcare’s By Your Side™ Lifetime Customer Care commitment to ensure that every customer achieves success and realizes the full value of their investment, through consulting, training, implementation and integration services. STANLEY Healthcare is proud to be part of Stanley Black & Decker, Inc. For more information, visit stanleyhealthcare.com. Follow STANLEY Healthcare on Facebook, Twitter, LinkedIn and YouTube.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Claudia Toscano
P: 210.477.8417
F: 210.348.1003
E: claudia.toscano@frost.com

PRNews

15 million Connected Disposable Medical Sensors to Ship by 2023

Vendors are investing to further the potential of a range of single-use, wireless healthcare sensors.

OYSTER BAY, N.Y., Sept. 7, 2017 /PRNewswire/ — The adoption of an emerging generation of disposable, connected sensors will be driven by the ongoing development of remote patient monitoring applications, according to the latest healthcare report from ABI Research. Combined with use in hospitals and clinics, shipments of single-use sensors capable of transmitting patient data wirelessly, will exceed 3.5 million sensors annually by 2022, growing at a CAGR of 30% from 2016 shipments.

“Disposables are already a feature of healthcare provision around the globe and medical sensors will have to fit into that world. Efforts already underway promise considerable progress over the next few years,” says Jonathan Collins, Research Director at ABI Research. “Their potential to extend and simplify the benefits of remote patient monitoring will help drive the adoption of both,” he says.

Disposable sensors, without embedded wireless transmitters are already commonplace in remote patient continuous glucose monitoring applications from Dexcom, Medtronic and others, but their potential reaches far beyond. Disposable connected sensors can support applications including medication tracking, temperature, heart rate and pulse oximetry as well as activity/movement/post-surgery orthopedics monitoring that address a far larger user-base.

A host of companies ranging from established players including Philips Healthcare and Medtronic to well-backed ventures like Qualcomm Life and smaller start-ups like GenTag and Proteus Digital Health are all investing in developing disposable sensors, but are taking varied approaches regarding sensor format and supporting technologies. In addition, a range of wireless protocols are under consideration for adoption in disposable smart health sensors including Bluetooth, NFC and Proprietary offerings.

“What these and many other companies share is an understanding that healthcare workflows and reimbursement payments are already steeped in the broad use of disposable devices. Between now and 2022 will be a key time for these vendors and others to address technical and ecosystem complexity around disposable sensor connectivity. It will also be the primary time for vendors to gain a foothold in the emerging market,” says Collins.

These findings are from ABI Research’s Disposable Medical Sensors report. This report is part of the company’s Smart Health research service, which includes research, data, and analyst insights. 

About ABI Research

ABI Research stands at the forefront of technology market intelligence, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

PRNews

Vatech Introduces the PaX-i Insight – the Latest Evolution in 2D Imaging

FORT LEE, N.J., Sept. 1, 2017 /PRNewswire/ —  Vatech officially launches the PaX-i Insight, the next generation of panoramic technology. PaX-i Insight aims to deliver an astonishing feature of adding depths to a panoramic image.


Depth added panoramic image

The all new PaX-i Insight features the ‘Insight Pan’, which is the 4th generation of panoramic radiography presented by Vatech for the first time in the market. While the conventional panoramic systems may miss important details which land outside of a single focal trough, the PaX-i Insight is capable of taking multi-layered images and providing in-depth look across a single focal trough.

Having the option to choose from a variety of images, the Insight Pan offers clinicians to explore 41 images (each sliced in 1 mm) when exploring their region of interest. This feature not only provides an accurate diagnosis for periapical diseases, periodontitis and pericoronitis but also allows clinicians to find hidden roots and canals.

In the case studies released by Vatech, visible fractured roots are often ‘missed out’ in conventional panoramic images with a single layer. Utilizing the PaX-i Insight’s ‘multi-slice’ mode, clinicians can discover buccal roots by examining each root and its periodontal ligament separately.

One notable feature of the PaX-i Insight is the 1.9 second acquisition time. Cephalometry radiography is an essential part of an orthodontic treatment and yet, it was not always easy to acquire a superb image quality that clinicians desire due to the motion artifact. Standing still for 12 seconds is difficult especially for children and teenagers. Furthermore, any movement during the image acquisition would leave clinicians with blurred images. Now with PaX-i Insight’s rapid ceph technology, clinicians can obtain accurate images in the shortest time span by minimizing motion artifacts.

Besides the functionality of the PaX-i Insight, the user-friendly EzDent-i software serves as a powerful solution to maximize the capability of the PaX-i Insight. The Easy-to-use interface allows clinicians to be more efficient with treatment planning and patient consultation. An efficient practice leads to a much better standard of care delivered to the patients.

“We are glad to present Vatech’s latest innovation which fascinated many clinicians at the IDS 2017. The new product will not only reduce the number of retakes by accurately exploring anatomical structures of the teeth but also enable faster diagnostic workflow. Since PaX-i Insight offers a unique feature which other products could not produce, we are all eager to see how this new product will transform the way clinicians work on their cases and communicate with their patients,” said Brian Hwang, CEO of Vatech America.

PaX-i Insight will make its first release in the United States. Shortly, the new product will be introduced to other global markets throughout the year; including Germany, Italy and France. For more information, please visit www.vatechamerica.com.

About Vatech America Inc.

Vatech is a leading provider of digital dental radiography products. As the US subsidiary of Vatech Co., Ltd., Vatech America is dedicated solely to innovative digital dental X-ray imaging technologies that aid dentists and ultimately help to improve the health of dental patients. The company is responsible for technological advances in recent years that offer every American dental practice, from small to large, endless possibilities to achieve higher standards.

PR Contact
June Chang
+1-201-210-5028
jchang@vatechamerica.com 
Vatech America


PaX-i Insight

View original content with multimedia:http://www.prnewswire.com/news-releases/vatech-introduces-the-pax-i-insight—the-latest-evolution-in-2d-imaging-300512079.html

Source: Vatech Co., Ltd.

PRNews

European XFEL: World’s Largest X-ray Laser to Launch in Hamburg

HAMBURG, Germany, Sept. 1, 2017 /PRNewswire/ —

From 1 September 2017, the European XFEL – the world‘s biggest X-ray laser – will be in regular operation. The €1.22 billion research facility in the Hamburg Metropolitan Region involves eleven European countries. 

The facility is a project of superlatives: with 27,000 X-ray laser flashes per second and a luminance a billion times higher than that of the best conventional X-ray sources, XFEL will open up entirely new research opportunities and help transcend the current boundaries of scientific research. It will enable international scientists to decipher the molecular composition of viruses and cells, take three-dimensional images of the nanoworld, film chemical reactions and study processes occurring deep inside planets. XFEL will help develop e.g. new medication and new materials.

This Friday, the facility will be launched by Germany’s Research Minister Johanna Wanka, Hamburg’s First Mayor Olaf Scholz, Schleswig-Holstein’s Science Minister Karin Prien, Russia’s Presidential Advisor Andrei Fursenko, French Research Minister Frédérique Vidal and other high-ranking representatives. They will be joined by several external researchers, who are currently preparing for their first experiments in mid-September.

XFEL is a non-profit organisation that closely collaborates with DESY Hamburg and other international institutions. It employs about 300 people. With a cost of €1.22 billion for construction and launch and a 3.4-kilometre tunnel system that extends to the state of Schleswig-Holstein, it is among Europe’s biggest and most ambitious research projects. Eleven countries are involved: Denmark, France, Germany, Hungary, Italy, Poland, Russia, Slovakia, Spain, Sweden, Switzerland; the UK is in the process of joining. For Hamburg as a science and business location, XFEL marks a further step in establishing itself as an international innovation hub.

More about XFEL: http://www.xfel.eu
More on Hamburg: http://www.hamburg.com

Hamburg Marketing
Guido Neumann
+49-40-300-583    
guido.neumann@marketing.hamburg.de

European XFEL GmbH
Dr Bernd Ebeling
+49-40-8998-6921
press@xfel.eu

PRNews

PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for Its Proprietary DETOUR System for Percutaneous Bypass

Novel technology enables a new, minimally invasive treatment for patients suffering from extremely long peripheral artery blockages

LONDON, Aug. 31, 2017 /PRNewswire/ — Frost & Sullivan is pleased to recognize PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award. PQ Bypass’ DETOUR System is a minimally invasive technology that enables physicians to re-direct, or detour, blood flow around extremely long blockages in the upper leg arteries to restore blood flow to the lower leg and foot.

“PAD is a potentially fatal condition that affects more than 200 million people worldwide—3 to 12% of the global population. PQ Bypass’ proprietary DETOUR System is a promising, innovative approach for patients with extremely long lesions whose current treatment options are not ideal,” said Frost & Sullivan Best Practices Analyst, Norma Vela. “We anticipate rapid, widespread technology adoption once the DETOUR System launches commercially. The global market potential for treating this type of advanced peripheral arterial disease is significant, and PQ Bypass has first-mover status in the space.”

Extremely long blockages in the leg arteries, especially those that are greater than 20 centimeters, are challenging to treat. Historically, physicians have treated these blockages with open bypass surgery (fem-pop bypass), which has the benefit of durability, however, it is associated with an increased risk of complications, longer hospital stays, and prolonged rehabilitation. More recently, minimally-invasive technologies have emerged that go through blockages. These technologies work very well on shorter blockages; however, they have not been as effective on these longer blockages as open surgery.

The DETOUR System is designed to deliver the durability advantages of open bypass surgery with a minimally-invasive approach. During a DETOUR procedure, a pathway is created by crossing from the SFA into the femoral vein and back into the artery that allows DETOUR stent grafts to be placed in a continuous line. The new path through the stent grafts re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient.

“With an increased focus on value-based and patient-centered medicine, surgical advancements that minimize trauma to patients, reduce length of hospital stay and recovery times are critical global needs,” said Richard Ferrari, Chairman of the Board of PQ Bypass. “We designed the DETOUR System to be a transformative step forward in how physicians treat extremely long peripheral artery disease.”

In March 2017, PQ Bypass received CE Mark approval for the DETOUR System and is planning a pivotal investigational device exemption study to support premarket approval from the US Food and Drug Administration (FDA). The clinical results of the DETOUR I trial conducted in Europe were promising, demonstrating excellent safety and effectiveness with patency results of 84.7% at 6 months.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and develops newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices Awards acknowledge companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally-invasive endovascular solutions.

PQ Bypass is operated by recognized leaders in the medical device industry. Our executive team members have held senior leadership positions at companies including Medtronic, Abbott, Johnson & Johnson, and Stryker and also have extensive experience developing medical devices for startups such as Evalve, Access Closure, Avinger, and DVI.

The underlying technology and technique used in the percutaneous PQ DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in PAD.

The PQ Bypass technology platform is not available for sale in the US. For more information, please visit www.pqbypass.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Fit Tech & Gadgets, PRNews

A Glimpse into the Future of Wearable Healthcare: Going Way Beyond Smartwatches and Fitness Trackers

OYSTER BAY, New York, Aug. 30, 2017 /PRNewswire/ — The healthcare wearables market accounts for US$6.8 billion of the current US$25 billion wearables market. ABI Research forecasts that Wearable Healthcare, including healthcare devices, sports, fitness, and wellness trackers will continue to dominate the wearables market and will exceed revenues of US$10 billion in 2022.

Healthcare wearables that monitor health conditions, physical performance, and brain activity will move beyond smartwatches and fitness trackers; they will shrink in size and change in form factor type. Unlike today’s bulky health related devices, ultra-thin and ultra-soft sensors with software analytics make next-generation wearables smarter and more useful. 

“As an ultimate form factor of wearables, flexible body-worn sensors are quite an innovation for wearable adoption in healthcare, fitness, and human-machine interface,” says Marina Lu, Senior Analyst at ABI Research. “These sensors can be integrated into a small patch and attached to human skin surface to track vital signs and other biometrics continuously and wirelessly. Some of the implementation examples include electronic tattoos and skin sweat sensors.”

The electronic tattoo developed by Rotex performs many of the typical functions of smart watches and fitness trackers. Not only does it monitor health conditions in real-time, it also provides a different means to control devices as an integral part of IoT. The low cost and disposability of the electronic tattoos further the use cases and value appeal of wearable technology, especially for customers who are price sensitive.

Replacing costly doctor visits and painful lab-based blood tests, non-invasive sweat sensors can measure a set of key biometrics from a single bead of sweat. A few companies are working to capture the sweat sensor market, such as Eccrine System, GraphWear Technologies and Kenzen.

These sensors require flexible components and startup Royole is leading the way. Royole’s plan for mass production of flexible displays and sensors will accelerate the technology adoption for wearables and facilitate more aesthetically-pleasing wearable designs, smaller form factors, and more immersive experiences.

“Health sensors are becoming increasingly commoditized, as they allow continuously physical monitoring with reduced manual intervention and at low cost,” concludes Lu. “While the miniaturized health sensors enable consumers to monitor health conditions by themselves and be aware of their own health care, they also extend to the enterprise market by delivering superior analytics for clinical and medical research. Once privacy and security concerns are addressed and standardization in health communication protocols are put into place, the next-gen of wearable healthcare will be ushered in.” 

These findings are from ABI Research’s Hot Tech Innovators: Wearables report. This report is part of the company’s Wearables, Usables & Expendables research service, which includes research, data, and analyst insights. 

About ABI Research

ABI Research stands at the forefront of technology market intelligence, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: 

Americas                                      

EMEA/APAC

Deborah Petrara                           

Denise Duffy

Tel: +1.516.624.2558                    

Tel: +44.203.326.0142

pr@abiresearch.com                      

duffy@abiresearch.com